Ken Griffin Recursion Pharmaceuticals, Inc. Put Options Transaction History

Citadel Advisors LLC

9 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2024 Nov 14, 2024	BUY	$5.92 - $8.6 $39,072 - $56,760	6,600 Added 1.2%	556,700 $3.67 Million
Q2 2024 Aug 14, 2024	BUY	$7.35 - $10.05 $2.3 Million - $3.14 Million	312,800 Added 131.82%	550,100 $4.13 Million
Q1 2024 May 15, 2024	BUY	$9.13 - $15.52 $1.4 Million - $2.37 Million	152,800 Added 180.83%	237,300 $2.37 Million
Q4 2023 Feb 14, 2024	BUY	$5.09 - $10.79 $5,090 - $10,790	1,000 Added 1.2%	84,500 $833,000
Q3 2023 Nov 14, 2023	BUY	$6.59 - $15.86 $498,204 - $1.2 Million	75,600 Added 956.96%	83,500 $638,000
Q2 2023 Aug 14, 2023	SELL	$4.56 - $9.94 $68,856 - $150,094	-15,100 Reduced 65.65%	7,900 $59,000
Q1 2023 May 15, 2023	BUY	$6.42 - $9.64 $139,314 - $209,188	21,700 Added 1669.23%	23,000 $153,000
Q4 2022 Feb 14, 2023	SELL	$7.16 - $12.7 $73,032 - $129,540	-10,200 Reduced 88.7%	1,300 $10,000
Q3 2022 Nov 14, 2022	SELL	$7.83 - $13.6 $28,971 - $50,320	-3,700 Reduced 24.34%	11,500 $122,000

286

242M

1.35M

2.32M

Ticker RXRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 180,480,000
Market Cap $1.33B
Description
Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase IIa clinical trial to treat cerebral cav...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.